Literature DB >> 10640284

Phosphorothioate oligodeoxynucleotides distribute similarly in class A scavenger receptor knockout and wild-type mice.

M Butler1, R M Crooke, M J Graham, K M Lemonidis, M Lougheed, S F Murray, D Witchell, U Steinbrecher, C F Bennett.   

Abstract

It has been suggested that binding of phosphorothioate oligodeoxynucleotides (P=S ODNs) to macrophage scavenger receptors (SR-AI/II) is the primary mechanism of P=S ODN uptake into cells in vivo. To address the role of scavenger receptors in P=S ODN distribution in vivo, several pharmacokinetic and pharmacological parameters were compared in tissues from scavenger receptor knockout mice (SR-A-/-) and their wild-type counterparts after i.v. administration of 5- and 20-mg/kg doses of P=S ODN. With an antibody that recognizes P=S ODN, no differences in cellular distribution or staining intensity in livers, kidneys, lungs, or spleens taken from SR-A-/- versus wild-type mice could be detected at the histological level. There were no significant differences in P=S ODN concentrations in these organs as measured by capillary gel electrophoresis as well, although the concentration of P=S ODN in isolated Kupffer cells from livers of SR-A-/- mice was 25% lower than that in Kupffer cells from wild-type mice. Furthermore, a P=S ODN targeting murine A-raf reduced A-raf RNA levels to a similar extent in livers from SRA-/- (92.8%) and wild-type (88.3%) mice. Finally, in vitro P=S ODN uptake studies in peritoneal macrophages from SR-A-/- versus wild-type mice indicate that other high- and low-affinity uptake mechanisms predominate. Taken as a whole, our data suggest that, although there may be some contribution to P=S ODN uptake by the SR-AI/II receptor, this mechanism alone cannot account for the bulk of P=S ODN distribution into tissues and cells in vivo, including macrophages.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10640284

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  27 in total

Review 1.  Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNA.

Authors:  Elias Fattal; Gillian Barratt
Journal:  Br J Pharmacol       Date:  2009-04-02       Impact factor: 8.739

Review 2.  Selective tissue targeting of synthetic nucleic acid drugs.

Authors:  Punit P Seth; Michael Tanowitz; C Frank Bennett
Journal:  J Clin Invest       Date:  2019-01-28       Impact factor: 14.808

3.  Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model.

Authors:  Yimin Hua; Kentaro Sahashi; Gene Hung; Frank Rigo; Marco A Passini; C Frank Bennett; Adrian R Krainer
Journal:  Genes Dev       Date:  2010-07-12       Impact factor: 11.361

Review 4.  Rekindling RNAi Therapy: Materials Design Requirements for In Vivo siRNA Delivery.

Authors:  Byungji Kim; Ji-Ho Park; Michael J Sailor
Journal:  Adv Mater       Date:  2019-09-30       Impact factor: 30.849

Review 5.  Receptor-Mediated Uptake of Phosphorothioate Antisense Oligonucleotides in Different Cell Types of the Liver.

Authors:  Colton M Miller; Michael Tanowitz; Aaron J Donner; Thazha P Prakash; Eric E Swayze; Edward N Harris; Punit P Seth
Journal:  Nucleic Acid Ther       Date:  2018-02-09       Impact factor: 5.486

6.  The role of the macrophage scavenger receptor in immune stimulation by bacterial DNA and synthetic oligonucleotides.

Authors:  F G Zhu; C F Reich; D S Pisetsky
Journal:  Immunology       Date:  2001-06       Impact factor: 7.397

7.  Modulation of plasma protein binding and in vivo liver cell uptake of phosphorothioate oligodeoxynucleotides by cholesterol conjugation.

Authors:  M K Bijsterbosch; E T Rump; R L De Vrueh; R Dorland; R van Veghel; K L Tivel; E A Biessen; T J van Berkel; M Manoharan
Journal:  Nucleic Acids Res       Date:  2000-07-15       Impact factor: 16.971

8.  Conformation of oligodeoxynucleotides associated with anionic liposomes.

Authors:  S D Patil; D G Rhodes
Journal:  Nucleic Acids Res       Date:  2000-11-01       Impact factor: 16.971

Review 9.  Bioconjugation of oligonucleotides for treating liver fibrosis.

Authors:  Zhaoyang Ye; Houssam S Hajj Houssein; Ram I Mahato
Journal:  Oligonucleotides       Date:  2007

Review 10.  Biological barriers to therapy with antisense and siRNA oligonucleotides.

Authors:  R Juliano; J Bauman; H Kang; X Ming
Journal:  Mol Pharm       Date:  2009 May-Jun       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.